[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2010002904A - N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv). - Google Patents

N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv).

Info

Publication number
MX2010002904A
MX2010002904A MX2010002904A MX2010002904A MX2010002904A MX 2010002904 A MX2010002904 A MX 2010002904A MX 2010002904 A MX2010002904 A MX 2010002904A MX 2010002904 A MX2010002904 A MX 2010002904A MX 2010002904 A MX2010002904 A MX 2010002904A
Authority
MX
Mexico
Prior art keywords
compounds
salts
hepatitis
useful
hcv
Prior art date
Application number
MX2010002904A
Other languages
English (en)
Inventor
David M Barnes
John K Pratt
David A Betebenner
Clarence J Maring
Rolf Wagner
John T Randolph
Douglas K Hutchinson
Allan C Krueger
Rodger F Henry
Brian J Kotecki
Anthony R Haight
Yi Gao
Kent D Stewart
Kenton L Longenecker
Todd W Rockway
Dachun Liu
Xiaochun Lou
Shuang Chen
Geoff G Z Zhang
Yaya Liu
Thaddeus S Ii Franczyk
John E Hengeveld
Pamela R Donner
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2010002904A publication Critical patent/MX2010002904A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se relaciona con: (a) compuestos y sales de los mismos que, entre otros, inhiben el HCV; (b) intermediarios de utilidad para la preparación de dichos compuestos y sales; (c) composiciones que comprenden dichos compuestos y sales; (d) métodos para preparar dichos intermediarios, compuestos, sales y composiciones; (e) métodos de uso de dichos compuestos, sales y composiciones; y (f) conjuntos de elementos que comprenden dichos compuestos, sales y composiciones. Los compuestos son útiles en el tratamiento de hepatitis C y tienen la siguiente estructura general: Formula (1).
MX2010002904A 2007-09-17 2008-09-17 N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv). MX2010002904A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97288707P 2007-09-17 2007-09-17
US9679408P 2008-09-13 2008-09-13
PCT/US2008/076594 WO2009039135A1 (en) 2007-09-17 2008-09-17 N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors

Publications (1)

Publication Number Publication Date
MX2010002904A true MX2010002904A (es) 2010-06-02

Family

ID=40091991

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002904A MX2010002904A (es) 2007-09-17 2008-09-17 N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv).

Country Status (15)

Country Link
US (2) US8178548B2 (es)
EP (3) EP2548873A1 (es)
JP (1) JP5726527B2 (es)
CN (3) CN101918369B (es)
AT (1) ATE512954T1 (es)
CA (1) CA2699989C (es)
DK (1) DK2203430T3 (es)
HK (1) HK1145839A1 (es)
HR (1) HRP20110632T1 (es)
MX (1) MX2010002904A (es)
PL (1) PL2203430T3 (es)
PT (1) PT2203430E (es)
RU (1) RU2542099C2 (es)
WO (1) WO2009039135A1 (es)
ZA (1) ZA201002690B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102746240B (zh) 2007-09-17 2017-10-03 艾伯维巴哈马有限公司 抗感染嘧啶及其用途
UA117800C2 (uk) 2007-09-17 2018-10-10 Еббві Айрленд Анлімітед Компані Похідні урацилу або тиміну для лікування гепатиту с
RU2542099C2 (ru) * 2007-09-17 2015-02-20 Эббви Бахамаз Лтд. N-фенил-диоксо-гидропиримидины, используемые в качестве ингибитора вируса гепатита с (hcv)
CN102099335A (zh) 2008-07-23 2011-06-15 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
WO2010034671A1 (en) 2008-09-26 2010-04-01 F. Hoffmann-La Roche Ag Pyrine or pyrazine derivatives for treating hcv
CA2741325A1 (en) 2008-10-30 2010-05-06 F. Hoffmann-La Roche Ag Heterocyclic antiviral arylpyridone derivatives
SG172778A1 (en) 2008-12-22 2011-08-29 Hoffmann La Roche Heterocyclic antiviral compounds
JP2012519661A (ja) 2009-03-06 2012-08-30 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス性複素環化合物
NZ594923A (en) * 2009-03-24 2013-11-29 Abbott Lab Process for preparing antiviral compound
CA2758838A1 (en) * 2009-04-25 2010-10-28 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
TWI428332B (zh) 2009-06-09 2014-03-01 Hoffmann La Roche 雜環抗病毒化合物
WO2010149598A2 (en) 2009-06-24 2010-12-29 F. Hoffmann-La Roche Ag Heterocyclic antiviral compound
MX2012003170A (es) 2009-09-21 2012-04-11 Hoffmann La Roche Compuestos heterociclicos antivirales.
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
JP2013511489A (ja) * 2009-11-21 2013-04-04 エフ．ホフマン−ラ ロシュ アーゲー 複素環式抗ウイルス化合物
WO2011072370A1 (en) * 2009-12-18 2011-06-23 Boehringer Ingelheim International Gmbh Hcv combination therapy
US9216952B2 (en) 2010-03-23 2015-12-22 Abbvie Inc. Process for preparing antiviral compound
RU2572558C2 (ru) * 2010-07-07 2016-01-20 Ф. Хоффманн-Ля Рош Аг Противовирусные гетероциклические соединения
MX338725B (es) 2010-07-16 2016-04-28 Abbvie Bahamas Ltd Ligando de fosfina para reacciones cataliticas.
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
EP3056486B1 (en) 2010-07-16 2018-07-11 AbbVie Ireland Unlimited Company Process for preparing intermediates for antiviral compounds
TWI558400B (zh) * 2011-03-18 2016-11-21 艾伯維有限公司 苯基尿嘧啶化合物之調配物
US8989328B2 (en) * 2013-03-14 2015-03-24 Qualcomm Incorporated Systems and methods for serial communication
PL3043803T3 (pl) 2013-09-11 2022-11-07 Emory University Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie
WO2015197028A1 (en) * 2014-06-28 2015-12-30 Sunshine Lake Pharma Co., Ltd. Compounds as hepatitis c virus (hcv) inhibitors and uses thereof in medicine
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
US11026958B2 (en) 2016-11-01 2021-06-08 Merck Sharp & Dohme Corp. Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors
CN110483496B (zh) * 2019-07-17 2021-05-04 杭州市西溪医院 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用
US20220387602A1 (en) * 2019-09-16 2022-12-08 Novartis Ag Bifunctional degraders and their methods of use
EP3819006A1 (en) 2019-11-05 2021-05-12 Technische Universität Dresden Compounds with thymine skeleton for use in medicine
CN111018910A (zh) * 2019-12-05 2020-04-17 上海应用技术大学 一种铜催化合成含芳环α-羟基膦酸酯的方法
CN111518036A (zh) * 2020-04-29 2020-08-11 杭州勇诚睿生物科技有限公司 一种达沙布韦关键中间体的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239888A (en) 1974-11-04 1980-12-16 Pfizer Inc. 1-Phenyluracils
JPS60243017A (ja) * 1984-05-16 1985-12-03 Kyowa Hakko Kogyo Co Ltd 抗けいれん組成物
US5084084A (en) 1989-07-14 1992-01-28 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
AU627906B2 (en) 1989-07-14 1992-09-03 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
EP0442473B1 (en) 1990-02-15 1998-08-19 Takeda Chemical Industries, Ltd. Pyrimidinedione derivatives, their production and use
NL9001075A (es) * 1990-05-04 1991-12-02 Duphar Int Res
EP0489480A1 (en) * 1990-12-05 1992-06-10 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
JPH05213755A (ja) 1992-02-07 1993-08-24 Nikko Kyodo Co Ltd 肝臓障害治療薬
DE19528305A1 (de) 1995-08-02 1997-02-06 Bayer Ag Substituierte Phenyluracile
PL207160B1 (pl) 1999-12-06 2010-11-30 Hoffmann La Roche Pochodne 4-pirymidynylo-N-acylo-L-fenyloalaniny, związki pośrednie, środek farmaceutyczny i ich zastosowanie
US6380387B1 (en) 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
IL167955A (en) 2000-02-04 2007-10-31 Sumitomo Chemical Co Inilines are converted by troiril
RU2264395C2 (ru) * 2000-02-04 2005-11-20 Сумитомо Кемикал Компани, Лимитед Производные урацила, гербицидная композиция, способ борьбы с сорняками и промежуточные продукты (варианты)
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR100589964B1 (ko) * 2003-06-13 2006-06-19 주식회사 엘지생명과학 Ｃ형 간염 바이러스의 억제제
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
RU2542099C2 (ru) * 2007-09-17 2015-02-20 Эббви Бахамаз Лтд. N-фенил-диоксо-гидропиримидины, используемые в качестве ингибитора вируса гепатита с (hcv)
UA117800C2 (uk) 2007-09-17 2018-10-10 Еббві Айрленд Анлімітед Компані Похідні урацилу або тиміну для лікування гепатиту с
CN102746240B (zh) 2007-09-17 2017-10-03 艾伯维巴哈马有限公司 抗感染嘧啶及其用途
CN102099335A (zh) 2008-07-23 2011-06-15 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物

Also Published As

Publication number Publication date
US8178548B2 (en) 2012-05-15
CN105294569A (zh) 2016-02-03
US8986740B2 (en) 2015-03-24
PT2203430E (pt) 2011-09-02
EP2203430B1 (en) 2011-06-15
RU2542099C2 (ru) 2015-02-20
HK1145839A1 (en) 2011-05-06
EP2377854A1 (en) 2011-10-19
US20090176784A1 (en) 2009-07-09
CN101918369A (zh) 2010-12-15
PL2203430T3 (pl) 2011-12-30
CA2699989A1 (en) 2009-03-26
JP2010539188A (ja) 2010-12-16
EP2548873A1 (en) 2013-01-23
US20120189580A1 (en) 2012-07-26
RU2010114826A (ru) 2011-10-27
ATE512954T1 (de) 2011-07-15
JP5726527B2 (ja) 2015-06-03
WO2009039135A1 (en) 2009-03-26
CN105693626A (zh) 2016-06-22
DK2203430T3 (da) 2011-09-26
HRP20110632T1 (hr) 2011-10-31
EP2203430A1 (en) 2010-07-07
ZA201002690B (en) 2015-12-23
CA2699989C (en) 2014-03-25
CN101918369B (zh) 2016-02-24

Similar Documents

Publication Publication Date Title
MX2010002904A (es) N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv).
MX2009004888A (es) Inhibidores del virus de la hepatitis c.
MX2009004943A (es) Inhibidores del virus de la hepatitis c.
MX2011009644A (es) Inhibidores del virus de la hepatitis c.
MX2013002927A (es) Inhibidores del virus de la hepatitis c.
NO20091845L (no) Macrocykliske peptider som hepatitt C virus-inhibitorer
NO20091846L (no) Makrocykliske peptider som hepatitt C virus- inhibitorer
PH12013500365A1 (en) Anti-infective agents and uses thereof
NO20075616L (no) Tripeptider som hepatitt C virus inhibitorer
PH12013500745A1 (en) Azaadamantane derivatives and methods of use
PH12014501134B1 (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
MX2013012749A (es) Inhibidores del virus de la hepatitis c.
MX2010002902A (es) Pirimidinas anti-infecciosas y usos de las mismas.
WO2008008776A3 (en) Hepatitis c virus inhibitors
MX2010008531A (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
EA201170153A1 (ru) Микроциклические производные индола, пригодные в качестве ингибиторов вируса гепатита с
MX2013014002A (es) Inhibidores del virus de la hepatitis c.
MX2008001541A (es) Metodos para la preparacion de inhibidores de polimerasa del vhc.
MX2013003551A (es) Formas en estado solido de un potente inhibidor del vch.
MX340085B (es) Inhibidores de hepatitis c y usos de los mismos.
CY1116537T1 (el) Ν-φαινυλ-διοξο-υδροπυριμιδινες χρησιμες ως αναστολεις ιου ηπατιτιδας c (hcv)
TN2013000135A1 (en) Solid state forms of a potent hcv inhibitor

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights